Ambulatory use of parenteral antibacterials: Contemporary perspectives

Drugs

Volumn 59, Issue SUPPL. 3, 2000, Pages 1-8

  Leggett, James E ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFAZOLIN; CEFONICID; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; FLEROXACIN; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; NAFCILLIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

CELLULITIS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HOME CARE; HUMAN; INFECTION; INFUSION PUMP; OTITIS MEDIA; REVIEW; URINARY TRACT INFECTION;

EID: 0033938930     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059003-00001     Document Type: Review

References (69)

1. MacGregor RR, Graziani A. Oral administration of antibiotics: a rational alternative to parenteral route. Clin Infect Dis 1997; 24: 457-67
2. Poretz DM. Evolution of outpatient parenteral antibiotic therapy. Infect Dis Clin North Am 1998; 12: 827-34
3. Bartlett JG. Impact of new oral antibiotics on the treatment of infectious diseases. Infect Dis Clin Pract 1993; 2: 405-13
4. Tice AD. Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 655-61
5. Gilbert DN, Dworkin RJ, Raber SR, et al. Outpatient parenteral antimicrobial-drug therapy. N Engl J Med 1997; 337: 829-38
6. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981; 3: 38-44
7. Craig WA. Selecting the antibiotic. Hosp Pract 1993; 28 Suppl. 1: 16-20
8. Andes D, Craig WA. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am 1998; 12: 849-60
9. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 636-42
10. Craig WA. Postantibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infection in man. J Antimicrob Chemother 1993; 31 Suppl. D: 149-58
11. Moore RD, Lietman PS, Smith CR. Clinical response to amino-glycoside therapy: importance of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9
12. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81
13. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-9
14. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-9
15. Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998; 77 (6 Suppl.): 7-11
16. Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med 1984; 77 Suppl. 6A: 43-50
17. Syndman DR, Cuchural GJ, McDermott L, et al. Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 1992; 36: 540-4
18. Weinstein MP, Stratton CW, Hawley HB, et al. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987; 83: 218-26
19. Romanelli G, Cravarezza P, and the Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J Antimicrob Chemother 1995; 36 (Suppl. A): 109-19
20. Leder K, Turnidge JD, Grayson JL. Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust 1998; 169: 519-22
21. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-60
22. Kale-Pradhan PB, Habowski SR, Chase HC. Once daily amino-glycosides: a meta-analysis of nonneutropenic and neutropenic adults. J Pharm Technol 1988; 14: 22-9
23. Craig WA. Once-daily dosing of aminoglycosides. Can J Infect Dis 1994; Suppl. C: 28-33
24. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989; 24: 281-93
25. Gilbert DN, Lee BL, Dworkin RJ, et al. A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am J Med 1998; 105: 182-91
26. Graninger W, Wenisch C, Wiesenger E, et al. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14: 11-5
27. New PB, Swanson GF, Bulich RG, et al. Ambulatory antibiotic infusion devices: extending the spectrum of outpatient therapies. Am J Med 1991; 91: 455-61
28. Williams DN, Gibson JA, Bosch D. Home intravenous antibiotic therapy using a programmable infusion pump. Arch Intern Med 1989; 149: 1157-60
29. Kravitz GR. Advances in IV delivery. Hosp Pract 1993; 28 Suppl. 1: 21-7
30. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-83
31. Bryan CS, Talwani R, Stinson MS. Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112: 1657-64
32. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27: 10-22
33. Russo TA, Cook S, Gorbach SL. Intramuscular ceftriaxone in home parenteral therapy. Antimicrob Agents Chemother 1988; 32: 1439-40
34. Neftel KA. Effect of storage of penicillin-G solutions on sensitization to penicillin-G after intravenous administration. Lancet 1982; 1: 986-8
35. Neftel KA, Walti M, Schulthess HK, et al. Adverse reactions following intravenous penicillin-G relate to degradation of the drugs in vitro. Klin Wochenschr 1984; 62: 25-9
36. Williams DN. Home intravenous anti-infective therapy (HIVAT) - do the benefits outweigh the risks. Drug Saf 1996; 14: 1-7
37. Nolet BR. Patient selection in outpatient parenteral antimicrobial therapy. Infect Dis Clin North Am 1998; 12: 835-47
38. Williams DN, Rehm SJ, Tice AD, et al. Practice guidelines for community-based parenteral anti-infective therapy. IDSA Practice Guidelines Committee. Clin Infect Dis 1997; 25: 787-801
39. Williams DN, Raymond JL. Practice guidelines for community-based parenteral anti-infective therapy. Infect Dis Clin North Am 1998; 12: 1009-21
40. Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient setting. Am J Surg 1984; 148 (4): 1-4
41. Poretz DM, Eron LJ, Goldenberg RI, et al. Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248: 336-9
42. Kunkel MJ, Iannini PB. Cefonicid in a once-daily regimen for treatment of osteomyelitis in an ambulatory setting. Rev Infect Dis 1984; 4: 865-9
43. Williams DN. Reducing costs and hospital stay for pneumonia with home intravenous cefotaxime treatment: results with a computerized ambulatory drug delivery system. Am J Med 1994; 97 Suppl. 2A: 50-5
44. Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med 1994; 97 Suppl. 2A: 28-33
45. Escalante CP, Rubenstein EB, Rolston KVI. Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Invest 1997; 15 (3): 237-42
46. Girmenia C, Moleti ML, Cartoni C, et al. Management of infective complications in patients with advanced hematologic malignancies in home care. Leukemia 1997; 11: 1807-12
47. Sahu S, Bapna A, Pai SK, et al. Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Pediatr Hematol Oncol 1997; 14: 205-11
48. Kaplinsky C, Drucker M, Goshen J, et al. Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 1994; 30: 649-51
49. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128: 847-9
50. Vinks AATMM, Brimicombe RW, Heijerman HGM, et al. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997; 40: 125-33
51. Wolter JM, Bowler SD, Nolan PJ, et al. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997; 10: 896-900
52. Pond MN, Newport M, Joanes D, et al. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. Eur Respir J 1994; 7: 1640-4
53. Poretz DM. Treatment of skin and soft-tissue infections utilizing an outpatient parenteral drug delivery device: a multicenter trial. Am J Med 1994; 97 Suppl. 2A: 23-7
54. Stamboulian D. Outpatient treatment of endocarditis in a clinic-based program in Argentina. Eur J Clin Microbiol Infect Dis 1995; 14: 648-54
55. Francioli P, Etienne J, Hoigne R, et al. Treatment of streptococcal endocarditis with single daily dose of ceftriaxone sodium for four weeks. Efficacy and outpatient treatment feasibility. JAMA 1992; 267 (2): 264-7
56. Wilson WR. Ceftriaxone sodium therapy of penicillin G-susceptible streptococcal endocarditis. JAMA 1992; 267: 279
57. Dimayuga E, Brown RB. Outpatient parenteral antibiotic therapy for infective endocarditis. Infect Dis Clin Pract 1995; 4: 468-71
58. Morales JO, Von Behren L. Secondary bacterial infections in HIV-inlected patients: an alternative ambulatory outpatient treatment utilizing intravenous cefotaxime. Am J Med 1994; 97 Suppl. 2A: 9-13
59. Tice AD (guest editor). Outpatient parenteral antimicrobial therapy. Infect Dis Clin North Am 1998; 12 (4)
60. Tice AD. Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 655-61
61. Nathwani D. Outpatient treatment with teicoplanin. Chemotherapie J 1996; 5 Suppl. 11: 35-8
62. Wilson APR, Gruneberg RN. Use of teicoplanin in community medicine. Eur J Clin Microbiol Infect Dis 1994; 13: 701-10
63. Eron LJ. Intravenous antibiotic administration in outpatient settings. Infect Dis 1982; 14: 4-11
64. Poretz DM, Eron LJ, Goldenberg RI. Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248: 336-9
65. Poretz DM, Woolard D, Eron LJ, et al. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 77: 77-83
66. Kind AC, Williams DN, Gibson J. Outpatient intravenous antibiotic therapy. Ten years' experience. Postgrad Med 1985; 77: 105-8, 111
67. Williams DN, Bosch D, Boots J, et al. Safety, efficacy and cost savings in an outpatient intravenous antibiotic program. Clin Ther 1993; 15 (1): 169-79
68. Tice AD. Patient selection criteria for outpatient parenteral antibiotic therapy - experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 23-9
69. Hindes R, Winkler C, Kane P, et al. Outpatient intravenous antibiotic therapy in medicare patients: cost-savings analysis. Infect Dis Clin Pract 1995; 4: 211-7